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Abstract
Background
The nucleotide analogue brincidofovir was developed to prevent and treat infections caused
by double-stranded DNA viruses. Based on in vitro data suggesting an antiviral effect
against Ebola virus, brincidofovir was included in theWorld Health Organisation list of
agents that should be prioritised for clinical evaluation in patients with Ebola virus disease
(EVD) during theWest African epidemic.
Methodsand Findings
In this single-armphase 2 trial conducted in Liberia, patients with laboratory-confirmedEVD
(two months of age or older, enrolment bodyweight50 kg) received oral brincidofovir 200
mg as a loading dose on day 0, followed by 100 mg brincidofovir on days 3, 7, 10, and 14.
Bodyweight-adjusted dosing was used for patients weighing <50 kg at enrolment. The pri-
mary outcomewas survival at Day 14 after the first dose of brincidofovir.
Four patients were enrolled between 01 January 2015 and 31 January 2015. The trial
was stopped following the decision by the manufacturer to terminate their program of devel-
opment of brincidofovir for EVD. No Serious Adverse Reactions or Suspected Unexpected
Serious Adverse Reactions were identified. All enrolled subjects died of an illness consis-
tent with EVD.
Conclusions
Due to the small sample size it was not possible to determine the efficacy of brincidofovir for
the treatment of EVD. The premature terminationof the trial highlights the need to establish
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Introduction
Prompted by the worsening Ebola virus epidemic inWest Africa theWorld Health Organisa-
tion (WHO) published an EmergencyUse Assessment and Listing procedure in September
2014 that identified a mechanism and candidate agents for therapeutic evaluation in patients
with Ebola virus disease (EVD) [1]. Brincidofovir (Chimerix Inc., Durham, North Carolina,
USA), an orally-available lipid conjugate of the licensed nucleotide analogue cidofovir, was
included in the initial list of agents prioritised for testing in clinical trials [2]. Brincidofovir has
broad-spectrumactivity against double-strandedDNA (dsDNA) viruses and was developed
for the treatment of severe infections including cytomegalovirus and adenovirus, and as a med-
ical countermeasure against smallpox [3]. For dsDNA viruses the active metabolite is cidofovir
diphospate (CDV-PP), which acts as an intra-cellular competitive substrate for the viral DNA
polymerase [4]. The antiviral activity of brincidofovir against Ebola virus (EBOV; a single-
stranded RNA virus) was indicated by in vitro studies of virus replication performed in 2014 by
the United States Centers for Disease Control and Prevention [2]. In October 2014 the United
States Food and Drug Administration (FDA) authorised brincidofovir for compassionate treat-
ment of patients with EVD through an emergency Investigational New Drug application
(eIND), and a phase 2 single-arm study was registered in the United States (NCT02271347).
Although the mechanism of action of brincidofovir in inhibiting replication of EBOV in
vitro was not known at the time, the decision to undertake this trial was made in the light of
continued support for the prioritization of brincidofovir by theWHOWorking Group on
Ebola Therapeutics, the knowledge that experiments in non-human primate (NHP) models of
EVD could not provide efficacy data since brincidofovir is metabolized differently by NHPs,
and the fact that brincidofovir was in late stage clinical development for other indications with
safety data available in>1000 subjects, some with life-threatening infections [5]. The prioriti-
sation of brincidofovir for evaluation in the 2014–16West Africa EVD outbreak was also sup-
ported by: oral dosing; low pill burden; product stability; immediate availability for use in
clinical trials; and potential scalability of production.
The Rapid Assessment of Potential Drugs and Interventions for Ebola (RAPIDE) clinical
trial platform was developed to assess potential treatments for EVD. The platform follows a
multi-stage approach described elsewhere [6]. This report describes one component of this
platform, the RAPIDE-brincidofovir trial, an open-label, non-randomised, single-arm trial of
brincidofovir for EVD.
Methods
Study Setting
ELWA-3 (Eternal LoveWinning Africa-3) Ebola treatment unit at the Ministry of Health com-
pound in Monrovia, Liberia, operated by Médecins Sans Frontières.
Brincidofovir for EVD
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publication and they do not necessarily represent the
decisions, policy or views of the WHO.
Study Design
An open-label, non-randomised, phase 2 single arm trial. Enrolled patients received brincido-
fovir in addition to standard supportive care. The primary outcome measure was survival,
assessed at 14 days after the first dose. The full protocol is available in the Supporting Informa-
tion (S1 File).
Statistical analysis plan
The RAPIDE-BCV trial was developed at the peak of the Ebola virus outbreak in 2014 as a
component of a research platform designed to evaluate a series of potential treatments as they
became available [6]. Brincidofovir would first be evaluated in a phase 2 trial with a maximum
of 140 patients without a concurrent control group, designed as a triage to classify the treat-
ment as (a) very effective, (b) promising or (c) apparently ineffective. Further details of the sta-
tistical methods are available in the Supporting Information (S1 and S2 Files). The need to
perform further trials and the trial design(s) required would be informed by the result of this
phase 2 trial [6]. The sequential data monitoring and primary outcome analysis was to be
based on outcomes in adult participants only.
Eligibility criteria and consent
Patients aged two months of age or older who were first diagnosedwith EBOV infection by
reverse transcription polymerase chain reaction (RT-PCR) in the preceding 48 hours were eli-
gible for inclusion.Women who were lactating had to agree to stop breastfeeding. Sexually-
active participants had to agree to use condoms for 3 months following discharge. All female
patients aged 15–49 years underwent pregnancy testing (blood or urine beta-HCG) and preg-
nant women were ineligible for the trial as embryotoxicity was detected in animal studies of
brincidofovir. Other exclusion criteria were: an underlying disease or condition that could
jeopardize the safety of the participant or others, or meant that the patient was unable to com-
ply with protocol requirements; inability to swallow; or known severe renal impairment,
defined as an estimated glomerular filtration rate (eGFR)<15 mL/min/1.73m2. Written
informed consent was obtained directly from competent adults, and from appropriate repre-
sentatives of participants<18 years of age or those who were too sick to consent.
Study treatment
A dosing regimen was selected based on the half maximal effective concentration (EC50)
against the Mayinga strain of Ebola Zaire in Huh7 cells, which were within the range of EC50s
observed for dsDNA viruses which had been effectively treated with brincidofovir in animal
models and humans, and the pharmacokinetics of brincidofovir in humans [3, 5, 7–10].
Patients with bodyweight50 kg at enrolment received 200 mg loading dose of brincidofovir
on day 0, followed by 100 mg brincidofovir on days 3, 7, 10, and 14. Patients with bodyweight
<50 kg received 4 mg/kg brincidofovir as an initial dose on day 0, followed by 2 mg/kg on days
3, 7, 10, and 14. Brincidofovir was administered orally, as tablets or dissolved in water. All
patients continued to receive supportive care in accordance with Médecins Sans Frontières
EVD treatment guidelines (including intravenous crystalloids or oral rehydration solution,
antimicrobials, antimalarials, analgesics, and nutritional support as prescribed by their treating
clinician).
Brincidofovir for EVD
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Safety reporting
Serious Adverse Reactions (SARs), SuspectedUnexpected Serious Adverse Reaction (SUSARs),
and key adverse events were assessed from the first dose to the primary outcome (day 14).
Severity of vomiting and diarrhoeawere categorised subjectively by clinical staff as mild, mod-
erate, or severe, since volumes of excreta and vomitus could not be measured reliably.
Laboratorymethods
Laboratory tests were limited to those requested by treating physicians. At the time of the trial,
local clinical diagnostic laboratories did not have the operational capacity to perform addi-
tional assays for research purposes. EBOV RT-PCR assays were performed by the CDC/NIH
laboratory associated with the ELWA-3 treatment unit. Haematology and biochemistry assays
were conducted on lithium-heparin plasma or whole blood using i-STAT1 (Abbott Point of
Care Inc., Princeton, NJ, USA) and/or Piccolo Xpress1 (Abbott Point of Care Inc., Princeton,
NJ, USA) point of care assays.
Ethics statement
The trial protocol was approved by the following research ethics committees: University of
Liberia—Pacific Institute for Research and Evaluation Institutional ReviewBoard,Monrovia,
Liberia;Oxford Tropical Research Ethics Committee, University of Oxford, UK; Médecins
Sans Frontières Ethics ReviewBoard, Geneva, Switzerland. Additional ethics advice was
received from theWHO Ethics ReviewCommittee. Approval to conduct the trial was granted
by the LiberiaMedicines and Health Products RegulatoryAuthority (LMHRA) and the Minis-
try of Health and SocialWelfare, Liberia. An Independent Data Monitoring Committee
reviewed data on a sequential basis, and reviewed any SARs, SUSARs, or other safety concerns.
Community awareness and engagement programmes were conducted by the University of
Oxford and Médecins Sans Frontières, supported by national collaborators and authorities.
The study was registered with the Pan African Clinical Trials Registry (PACTR2014110009
39962). The trial was conducted in compliance with the International Conference on Harmoni-
sation Guidance on GoodClinical Practice (GCP), for which the LMHRA conducted compli-
ance monitoring during the trial.
Results
Four previously healthy participants with EVD were enrolled (two adults and two children)
between 01 January 2015 and 31 January 2015 (Table 1). The CONSORT flow diagram is
shown in Fig 1. On admission, all four participants had at least one feature associated with a
high risk of death [11–15]. Participants 1 and 4 had haemorrhagic symptoms, and Participants
2 and 3 had Ebola virus RT-PCR cycle threshold values of 20. On admission, Participant 2 had
evidence of hepatic injury (alanine aminotransferase concentration 750 U/L) and Participant 3
had evidence of dehydration (high haematocrit and haemoglobin) and renal impairment. Par-
ticipant 4, a child, was enrolled with consent provided by a family member, which was with-
drawn on day 2 of treatment by a more senior family member. The trial closed to recruitment
on 31 January 2015 when the manufacturer ceased participation in all trials of brincidofovir for
EVD.
No patient completed the treatment course and none survived to day 14 (Table 2). Two par-
ticipants received only the first dose: consent was withdrawn for Participant 4, and treatment
was suspended for Participant 3 because of worsening pre-existing renal impairment (eGFR
<15 mL/min/173m2). Further clinical details of the participants are provided in the
Brincidofovir for EVD
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Supplementary Information (S3 File and S1 Table). All four deaths were consistent with severe
EVD. Analysis of primary outcome data from the two adult patients was not undertaken
because the sample size was insufficient to draw meaningful conclusions.
No Serious Adverse Reactions or SuspectedUnexpected Serious Adverse Reactions were
identified.However the scheduled administration of the day 7 dose of brincidofovir was sus-
pended for 24 hours in Participant 2 because of concerns that brincidofovirmight be contribut-
ing to persistent diarrhoea. The patient died before a decision to continue the study drug could
be made.
Discussion
We report our experience of conducting a trial of brincidofovir for the treatment of EVD. We
were unable to complete the trial or draw conclusions regarding drug efficacy due to slow
recruitment (caused by falling case numbers in Liberia) and by the decision of Chimerix, Inc.
to terminate their program of development of brincidofovir for EVD and to terminate the clini-
cal trial agreement.
All four patients died, with illnesses consistent with severe EVD. There were no SARs or
SUSARs reported. There was a possible temporal association between brincidofovir adminis-
tration and worsening diarrhoea in one patient. Diarrhoea is the main dose-limiting toxicity
observedwith brincidofovir in other conditions but is most common after two weeks of ther-
apy (personal communication Chimerix, Inc.)[16]. Since diarrhoea is very common in EVD
and large volume watery diarrhoea is a reported in severe EVD, it is difficult to differentiate
between diarrhoea as a symptom of EVD and diarrhea due to brincidofovir administration [15,
17–21].
Our study highlights the substantial uncertainties associated with the conduct of a trial of
an experimental therapeutic under emergency conditions. Data on potential therapeutics were
accruing during the trial set up and it was necessary to convene a special meeting of theWHO
Table 1. Demographic and clinical features at enrolment.
At enrolment Participant 1 Participant 2 Participant3 Participant 4
Age group (years) 20–29 10–14 40–49 10–14
Sex F M F F
BodyWeight (kg) 54 37 65 28
Self reportedduration of illness (days prior to enrolment) 3 7 2 3
EBOV RT-PCR cycle threshold value 2270 2066 2080 2674
Temperature (°C) 371 371 356 383
Heart rate (per minute) 104 102 112 98
Respiratory rate (per minute) 30 26 28 26
Systolic blood pressure (mmHg) 90 118 127 98
Diastolic blood pressure (mmHg) 65 75 96 56
HIV treatment in previous two weeks No No No No
Intravenous fluids in last 24 hours (volume in litres) No No Yes (26) Yes (15)
Oral rehydration fluids in last 24 hours Yes Yes Yes No
Malaria rapid test Negative Negative Negative Negative
Diarrhoea reported (severity*) No Yes (+) Yes (+) Yes(++)
Vomiting reported (severity*) Yes (++) Yes (+) Yes (+) No
Bleeding reported Yes Yes (haematemesis) No No Yes (epistaxis, Yes, (gingival)
* Physician assessed severity of vomiting and diarrhoea: + = mild; ++ = moderate; +++ = severe.
doi:10.1371/journal.pone.0162199.t001
Brincidofovir for EVD
PLOSONE | DOI:10.1371/journal.pone.0162199 September 9, 2016 5 / 10
Fig 1. CONSORT FlowDiagram.Consortdiagram of patients eligible, recruited, numbers followed up and included in analysis.
doi:10.1371/journal.pone.0162199.g001
Brincidofovir for EVD
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Working Group on Ebola Therapeutics in December 2014 (prior to initiating recruitment) to
provide an expert opinion on the interpretation of new animal data for brincidofovir. The
Working Group concluded that the new results were inconclusive and brincidofovir should
remain a priority candidate for testing in EVD patients. On 30 January 2015 Chimerix, Inc.
suspended the development of brincidofovir for EVD and withdrew from the trial [22]. On
18th February 2015, after the trial had closed to recruitment, brincidofovir was deprioritised by
WHO based on new data bringing into doubt its anti-EBOV activity [1]. Prior to this change of
status, brincidofovir had been given under an eIND to five medically evacuated EVD patients
[18, 23], was registered for a phase 2 trial in the United States, and was used in our trial in Libe-
ria. Subsequent work has identified that the lipid-nucleotide conjugate rather than the nucleo-
tide itself is responsible for the inhibition of EBOV replication in cell culture [7]. Since the
plasma half-life of the lipid-nucleotide conjugate is much shorter than the intra-cellular half-
life of CDV-PP, the brincidofovir dose and schedule used on a compassionate basis, in animal
studies, and in this trial is likely to have been insufficient to inhibit EBOV replication since dos-
ing was based on the assumption that CDV-PP was the active agent. The inconsistent pre-clini-
cal data, and differing opinions on their interpretation, highlight the need to develop and agree
better practices for preclinical in-vitro and animal screening of therapeutics for potentially
emerging epidemic infectious disease prior to their use in patients. In the absence of evidence
of clinical effectiveness in a validated animal model of infection, it is vital that the mechanism
of action and the pharmacokinetics of the active moiety are established. It is also important
that when data are emerging and opinion is divided during a public health emergency, both the
data and the differing opinions about its interpretation are made readily available so that clini-
cians can reach informed decisions about whether to proceed with clinical studies. This will
maximise the likelihoodof identifying effective treatments and will reduce the risk and poten-
tial associated harms of failed trials.
Supporting Information
S1 File. Trial protocol and statistical analysis plan.
(PDF)
S2 File. Statisticalmethods.
(DOCX)
S3 File. Additional clinical details of trial participants.
(DOCX)
Table 2. Treatment and clinical progression during admission.
Participant
Description [normal range] Study Day 1 2 3 4
Brincidofovir (weight adjusted dose) Day 0 Y (200mg) Y (150mg) Y (200mg) Y (110mg)
Day 1 N N N Withdrew
Day 2 N N N
Day 3 Y (100mg) Y (75mg) N / Died
Day 4 N N
Day 5 N N
Day 6 N N
Day 7 Y (100mg) / Died N / Died
doi:10.1371/journal.pone.0162199.t002
Brincidofovir for EVD
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S4 File. CONSORT Checklist.
(DOC)
S1 Table. Treatment and clinical progression during admission.
(DOCX)
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